Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Janssen Biotech and Pharmacyclics LLC, an AbbVie Company, and BeiGene.

Advances In™ CLL: Individualizing Patient Care With BTK Inhibitors

Release Date: July 30, 2021
Expiration Date: July 30, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of chronic lymphocytic leukemia (CLL), with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of molecular testing, clinical trial data, current and emerging treatment strategies, and management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Janssen Biotech and Pharmacyclics LLC, an AbbVie Company, and BeiGene.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward oncologists, hematologists, and pathologists involved in the treatment and management of chronic lymphocytic leukemia. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals (HCPs) involved in the management of patients with hematologic malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Understand the biological rationale for BTK inhibition strategies in CLL management
  • Assess emerging clinical trial data regarding the use of BTK inhibitors in the treatment of CLL
  • Tailor treatment with BTK inhibitors for individualized care in patients with CLL
  • Evaluate strategies to monitor and mitigate adverse events associated with BTK inhibitor treatment

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Farrukh Y Awan, MD
Farrukh Y Awan, MD
Associate Professor of Internal Medicine
Director Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, TX

Disclosures: Consultant: AbbVie, ADC Therapeutics, BeiGene, Bristol Myers Squibb, Cardinal Health, Celgene, DAVA Oncology, Genentech, Gilead, Incyte, Janssen, Johnson & Johnson, Karyopharm, Kite Pharma, MEI Pharma, Merck, Pharmacyclics, Verastem Oncology.

Jennifer R Brown, MD, PhD
Jennifer R Brown, MD, PhD
Director, CLL Center
Division of Hematologic Malignancies
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: Gilead, Loxo Oncology/Lilly, Secura Bio, Sun Pharma, TG Therapeutics; Consultant: AbbVie, Acerta Pharma/AstraZeneca, BeiGene, Bristol Myers Squibb/Juno/Celgene, Catapult Therapeutics, Eli Lilly, Genentech/Roche, Janssen, MEI Pharma, MorphoSys AG, Nextcea, Novartis, Pfizer, Rigel; Other: Data Safety Monitoring Committee Service: Invectys.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By